Trials / Terminated
TerminatedNCT00124891
Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia
Study Evaluating Subjects With Non-sustained Ventricular Tachycardia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Double-blind investigational anti-arrhythmic | |
| DRUG | GAP-486 |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2005-07-28
- Last updated
- 2022-05-03
Locations
75 sites across 16 countries: United States, Brazil, Canada, Croatia, Denmark, Hungary, India, Italy, Mexico, Poland, Romania, Russia, Serbia, Sweden, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00124891. Inclusion in this directory is not an endorsement.